Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 28;14:4551. doi: 10.1038/s41467-023-40272-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — Neutralizing antibody titers against the Ancestral (a), Gamma (b), Delta (c), Omicron BA.1 (d) and Omicron BA.5 (e) variants of SARS-CoV-2 in plasma samples of individuals boosted with ARVAC CG 25 µg (left panels) or 50 µg (right panels) prior to the vaccine administration (d1) or after 14 days of booster (d14). Participants in each cohort were grouped according to the primary vaccination scheme received. ARVAC CG 25 µg cohort: BBIBP-CorV (N = 20), ChAdOx1-S (N = 17), rAd26/rAd5 (N = 21), rAd26/ChAdOx1-S (N = 1) and Ad5-nCoV (N = 1). ARVAC CG 50 µg cohort: BBIBP-CorV (N = 14), ChAdOx1-S (N = 1), rAd26/rAd5 (N = 1), heterologous vaccination regimens (ChAdOx1-S/mRNA1273 or BBIBP-CorV/BNT162b2) (N = 3) and Ad26.CoV2.S (N = 1). Each point represents the nAb titer of a volunteer. In subgroups with N > 1, the nAb GMTs with geometric SD are shown as horizontal and error bars, respectively. The numbers depicted above the individual points for each specified time point represent the GMT values. The GMFR from day 1 to day 14 for each specified variant are shown with a number followed by a ×. The number of participants included in each data set analyzed are depicted in the bottom of each data set (N). Statistical differences were performed using the two-tailed Wilcoxon pair-matched test. P-values are depicted above the data sets that were compared. Exact P-values (d1 vs. d14 nAb titers) in ARVAC CG 25 µg subgroups (left panels) are: BBIBP-CorV (P = 0.000002 (a, b, d), P = 0.00003 (c), and P = 0.000004 (d, e), ChAdOx1-S (P = 0.000002 (a, b, c) and P = 0.00002 (d, e). In ARVAC CG 50 µg BBIBP-CorV primary vaccination exact P-values are: P = 0.0002 (a, b, d), P = 0.0001 (c) and P = 0.0005 (e).